[go: up one dir, main page]

DK1621077T3 - Farmaceutiske præparater der omfatter arsentrioxid til behandling af ikke-Hodkins lymfom - Google Patents

Farmaceutiske præparater der omfatter arsentrioxid til behandling af ikke-Hodkins lymfom

Info

Publication number
DK1621077T3
DK1621077T3 DK05077338T DK05077338T DK1621077T3 DK 1621077 T3 DK1621077 T3 DK 1621077T3 DK 05077338 T DK05077338 T DK 05077338T DK 05077338 T DK05077338 T DK 05077338T DK 1621077 T3 DK1621077 T3 DK 1621077T3
Authority
DK
Denmark
Prior art keywords
hodkin
lymphoma
arsenic trioxide
treatment
pharmaceutical compositions
Prior art date
Application number
DK05077338T
Other languages
Danish (da)
English (en)
Inventor
Ralph M Ellison
Fred H Mermelstein
Original Assignee
Polarx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polarx Biopharmaceuticals Inc filed Critical Polarx Biopharmaceuticals Inc
Application granted granted Critical
Publication of DK1621077T3 publication Critical patent/DK1621077T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DK05077338T 1997-10-15 1998-10-15 Farmaceutiske præparater der omfatter arsentrioxid til behandling af ikke-Hodkins lymfom DK1621077T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6237597P 1997-10-15 1997-10-15
PCT/US1998/021782 WO1999018798A1 (fr) 1997-10-15 1998-10-15 Compositions et methodes de traitement de maladies neoplasiques primitives et metastatiques a l'aide de composes d'arsenic

Publications (1)

Publication Number Publication Date
DK1621077T3 true DK1621077T3 (da) 2009-01-26

Family

ID=22042073

Family Applications (4)

Application Number Title Priority Date Filing Date
DK03019628T DK1391206T3 (da) 1997-10-15 1998-10-15 Farmaceutiske præparater der omfatter arsentrioxyd til behandling af ikke-Hodgkins lymfom
DK05077338T DK1621077T3 (da) 1997-10-15 1998-10-15 Farmaceutiske præparater der omfatter arsentrioxid til behandling af ikke-Hodkins lymfom
DK03019594T DK1378240T3 (da) 1997-10-15 1998-10-15 Farmaceutiske præparater omfattende arsentrioxid til behandling af multipelt myelom
DK08016665.5T DK2018858T3 (da) 1997-10-15 1998-10-15 Sammensætninger og fremgangsmåder til behandlingen af primære og metastatiske neoplastiske sygdomme ved anvendelse af arsentrioxid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03019628T DK1391206T3 (da) 1997-10-15 1998-10-15 Farmaceutiske præparater der omfatter arsentrioxyd til behandling af ikke-Hodgkins lymfom

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK03019594T DK1378240T3 (da) 1997-10-15 1998-10-15 Farmaceutiske præparater omfattende arsentrioxid til behandling af multipelt myelom
DK08016665.5T DK2018858T3 (da) 1997-10-15 1998-10-15 Sammensætninger og fremgangsmåder til behandlingen af primære og metastatiske neoplastiske sygdomme ved anvendelse af arsentrioxid

Country Status (20)

Country Link
US (9) US6875451B2 (fr)
EP (9) EP1022951A4 (fr)
JP (1) JP2001519366A (fr)
KR (1) KR20010015755A (fr)
CN (1) CN1282218A (fr)
AT (4) ATE409043T1 (fr)
AU (1) AU751932B2 (fr)
BR (1) BR9813085A (fr)
CA (1) CA2307208A1 (fr)
CY (4) CY1108363T1 (fr)
DE (4) DE69840006D1 (fr)
DK (4) DK1391206T3 (fr)
ES (4) ES2312701T3 (fr)
IL (1) IL135620A0 (fr)
NO (1) NO20001977L (fr)
NZ (1) NZ503973A (fr)
PL (1) PL339909A1 (fr)
PT (4) PT2018858E (fr)
TR (1) TR200001959T2 (fr)
WO (1) WO1999018798A1 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
DE10196619D2 (en) * 2001-07-05 2004-05-06 Hans-Werner Luedke Nahrungsergänzungsprodukt oder arzneimittel gegen bestimmte mangelzustände und hirnfunktionsstörungen
AUPR874601A0 (en) 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
KR20030058019A (ko) * 2001-12-29 2003-07-07 한국원자력연구소 삼산화비소(Ａｓ₂Ｏ₃)를 유효 성분으로 포함하는 방사선치료증진제
EP2462932A1 (fr) * 2002-01-07 2012-06-13 Board Of Regents, The University Of Texas System Acide S-diméthylarsino-thiosuccinique, acide S-diméthylarsino-2-thiobenzoïque et S-(diméthylarsino) glutathione en tant que traitements pour le cancer
JP2005525397A (ja) * 2002-04-10 2005-08-25 コリア マイクロバイオロジカル ラボラトリーズ リミテッド 悪性腫瘍の処置のための亜ヒ酸塩を含む薬学的組成物
US8394422B2 (en) * 2002-04-26 2013-03-12 Centre National De La Recherche Scientifique (Cnrs) Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
KR100492940B1 (ko) * 2002-05-27 2005-06-02 김종배 항종양활성 증진용 조성물
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
US20080089949A1 (en) * 2006-10-13 2008-04-17 Yok-Lam Kwong Method for treating cancer using oral arsenic trioxide
US8906422B2 (en) * 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US20080166425A1 (en) * 2002-10-09 2008-07-10 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US20060166208A1 (en) 2002-11-07 2006-07-27 Hogg Philip J Induction of the mitochondrial permeability transition
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005062810A2 (fr) * 2003-12-18 2005-07-14 Mediscovery, Llc Traitement de maladies neoplasiques metastatiques ou primiares avec du decaoxyde d'arsenic
KR20060125916A (ko) * 2004-03-01 2006-12-06 펩팀문, 인코포레이티드 자가면역 질병을 치료하기 위한 방법 및 조성물
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US20050208149A1 (en) * 2004-03-18 2005-09-22 Tty Biopharm Limited Company Use of arsenic-containing pharmaceutical composition in combination with radiation therapy for cancer treatment
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
AU2005257982B8 (en) 2004-06-16 2011-03-10 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
WO2006024489A2 (fr) * 2004-08-30 2006-03-09 Interstitial Therapeutics Procedes et compositions pour le traitement de la proliferation cellulaire
WO2006102439A2 (fr) 2005-03-23 2006-09-28 Florida Atlantic University Traitement ou prevention du cancer et de troubles precancereux
EP1721615A1 (fr) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Composition pharmaceutique comprenant de l'arsenite de sodium ou de potassium pour traiter le cancer urogenital et ses métastases
ES2532666T3 (es) 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
WO2007028154A2 (fr) * 2005-09-02 2007-03-08 Northwestern University Medicaments arsenicaux encapsules
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
US8784899B2 (en) * 2005-10-04 2014-07-22 Samuel Waxman Cancer Research Foundation Compositions and methods for cancer treatment
US20080233207A1 (en) * 2006-01-04 2008-09-25 Sheptovitsky Yelena G Injectable and Infusable Mercury Compositions and Methods for Treating Cancer
ITMI20060480A1 (it) * 2006-03-16 2007-09-17 Solvay Solexis Spa Usom di perfluoropolimeri nella dtermibnazione della costante di legame recettore-ligando
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
WO2008046299A1 (fr) * 2006-10-11 2008-04-24 The University Of Hong Kong Procédé d'inhibition du cancer au moyen de trioxyde d'arsenic
CA2668010C (fr) 2006-11-01 2015-03-24 Newsouth Innovations Pty Limited Composes d'organo-arsenoxydes et leur utilisation
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
JP5693850B2 (ja) 2007-02-06 2015-04-01 リクスト・バイオテクノロジー，インコーポレイテッド オキサビシクロヘプタンおよびオキサビシクロヘプテン、それらの製造および使用
AU2008284364A1 (en) * 2007-08-03 2009-02-12 Lixte Biotechnology, Inc. Use of phosphatases to treat neuroblastomas and medulloblastomas
ES2628748T3 (es) 2007-10-01 2017-08-03 Lixte Biotechnology, Inc. Inhibidores de la HDAC
KR20100100835A (ko) * 2007-11-02 2010-09-15 지오팜 온콜로지 인코포레이티드 유기 비소제와의 병용 요법
CN104592302A (zh) * 2007-12-12 2015-05-06 日本苏爱康制药有限公司 用于治疗癌症的化合物和方法
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US8227473B2 (en) * 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
CA2730428A1 (fr) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Procedes de regulation de la mitose cellulaire par inhibition de la phosphatase de serine/threonine
WO2010147612A1 (fr) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Procédés de modulation de la régulation cellulaire par inhibition de p53
WO2010014220A1 (fr) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Agents neuroprotecteurs pour la prévention et le traitement de maladies neurodégénératives
RU2534606C2 (ru) 2008-08-20 2014-11-27 Зайофарм Онколоджи, Инк. Мышьякорганические соединения и способы лечения рака
KR101100786B1 (ko) * 2008-12-16 2011-12-29 (주)천지산 암에 대한 방사선 치료 증진용 조성물
KR20120061908A (ko) * 2009-09-10 2012-06-13 코미녹스 인코포레이티드 암 줄기세포-표적 및 약물 내성 암 치료
WO2011034775A2 (fr) * 2009-09-18 2011-03-24 Kominox Usa, Inc. Méthodes de traitement de tumeurs cérébrales
US20120015023A1 (en) * 2010-04-15 2012-01-19 Antimisiaris Sophia G Treatment of tumors prostate with arsonoliposomes
WO2014152330A1 (fr) * 2013-03-15 2014-09-25 Stc.Unm Traitement à base d'arsenic de cancers et de troubles inflammatoires
US20160015743A1 (en) * 2013-03-15 2016-01-21 Rush University Medical Center Methods for treating cancer
EA201591931A1 (ru) 2013-04-09 2016-05-31 Ликсте Байотекнолоджи, Инк. Композиции оксабициклогептанов и оксабициклогептенов
FR3004949B1 (fr) * 2013-04-26 2016-02-05 Centre Nat Rech Scient Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale
US9700580B1 (en) 2016-06-14 2017-07-11 Marguerite Harning Method for cancer treatment
PE20191544A1 (es) 2016-12-01 2019-10-24 Eupharma Pty Ltd Composiciones de arsenico
ES2970913T3 (es) 2016-12-08 2024-05-31 Lixte Biotechnology Inc Oxabicicloheptanos para modulación de la respuesta inmunitaria
KR101844050B1 (ko) * 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
WO2018209343A1 (fr) * 2017-05-12 2018-11-15 Rajur Sharanappa Basappa Nouveaux procédés, composés et compositions : agents anticancéreux à petites molécules
WO2019234112A1 (fr) 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Traitement combinatoire à base d'oxyde d'arsenic et d'anti-androgènes
CN112675197A (zh) * 2021-01-22 2021-04-20 中山大学孙逸仙纪念医院 一种用于儿童Hedgehog信号通路驱动肿瘤的药物组合物
US20240139108A1 (en) * 2021-02-26 2024-05-02 Intas Pharmaceuticals Ltd. Oral pharmaceutical composition of arsenic trioxide
CN114028425A (zh) * 2021-09-24 2022-02-11 上海交通大学医学院附属新华医院 硫化砷及其与放疗联合在治疗横纹肌肉瘤上的应用
CN115634287A (zh) * 2022-09-30 2023-01-24 苏州系统医学研究所 一种基于砷化合物的肿瘤疫苗及其制备方法和应用
DE102023114756B4 (de) 2023-06-06 2025-03-13 Schaeffler Technologies AG & Co. KG Bremsvorrichtung mit Kühlstruktur sowie Fahrzeug mit der Bremsvorrichtung
DE102023123189B4 (de) 2023-08-29 2025-03-13 Schaeffler Technologies AG & Co. KG Bremsvorrichtung mit einer Synchroneinrichtung für ein Fahrzeug sowie Fahrzeug mit der Bremsvorrichtung
DE102023123190B4 (de) 2023-08-29 2025-03-13 Schaeffler Technologies AG & Co. KG Bremsvorrichtung mit einer Mehrzahl von Bremsscheiben sowie Fahrzeug mit der Bremsvorrichtung
DE102023123187B4 (de) 2023-08-29 2025-03-13 Schaeffler Technologies AG & Co. KG Bremsvorrichtung für ein Fahrzeug, Antriebsanordnung mit der Bremsvorrichtung sowie Fahrzeug
DE102023123673B4 (de) 2023-09-04 2025-03-13 Schaeffler Technologies AG & Co. KG Bremsvorrichtung mit einer Magnetkupplungseinrichtung für ein Fahrzeug sowie Fahrzeug mit der Bremsvorrichtung

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US232807A (en) 1880-10-05 Herbert e
US132275A (en) 1872-10-15 Improvement in medical compounds
US3700498A (en) 1970-12-10 1972-10-24 Ibm Process for making electrophotographic plates
JPS5188620A (en) 1975-01-31 1976-08-03 Jintainokenkonoiji kotonigannitaishitekonoojusuru noshukuionekinoseizoho
DE3003635C2 (de) 1980-02-01 1985-07-11 Klöckner-Humboldt-Deutz AG, 5000 Köln Verfahren und Vorrichtung zur Entarsenierung arsenhaltiger Materialien
US4599305A (en) * 1984-07-16 1986-07-08 The Regents Of The University Of California Method and composition for detection of human chronic myelogenous leukemia
NL8502929A (nl) * 1985-10-25 1987-05-18 Tno Groep viii-overgangsmetaal-complexen, werkwijze voor het bereiden daarvan, werkwijze voor het bereiden van een geneesmiddel met toepassing van een dergelijke groep viii-overgangsmetaal-complex voor de behandeling van kanker, alsmede aldus verkregen gevormd geneesmiddel.
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
CN1061908A (zh) 1991-12-21 1992-06-17 江西省妇产医院 一种治癌药物的制造方法
CN1060935C (zh) 1992-05-31 2001-01-24 丛繁滋 用于癌病灶直接给药的砷制剂的制备方法
CN1044777C (zh) 1992-07-06 1999-08-25 杨世泽 癌痛止痛膏的配制方法
KR100329245B1 (ko) 1992-07-24 2002-03-18 더 존스 홉킨스 유니버시티 종양 세포의 발병도를 측정하는 것을 돕는 생체외 분석방법
FR2699820B3 (fr) * 1992-12-24 1995-03-10 Eric Pichot Traitement homéopathique préventif des dysmytoses (cancer, leucémie) et malformations ou mutations génétiques.
DE4317331A1 (de) * 1993-05-25 1994-12-01 Reischle Karl Georg Behandlung von Schädigungen des Immunsystems
ITTO930510A1 (it) 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
WO1995022336A1 (fr) 1994-02-18 1995-08-24 Tamara Vasilievna Vorobieva Agent immunomodulateur et reducteur du dysfonctionnement du systeme de regulation de la propagation de cellules tissulaires
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
CN1119113A (zh) 1994-09-22 1996-03-27 衣永德 复方癌复康胶囊及制备方法
CN1122700A (zh) 1994-11-08 1996-05-22 付知中 一种治疗乳腺疾病、肿瘤疮毒的散剂及其制备方法
LV11667B (en) * 1995-08-14 1997-06-20 Tamara Vorobieva Remedy for renewal of disordered function of immunomodulation and cell tissue reproduction adjustors
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
CA2233960A1 (fr) * 1995-10-06 1997-04-10 Photoelectron Corporation Appareil ameliore pour appliquer des rayons x sur une surface interieure d'une cavite d'un corps
CN1058620C (zh) 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
CN1052648C (zh) 1995-12-03 2000-05-24 唐书生 癌瘤消肿止痛膏
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
ES2285251T3 (es) * 2002-09-24 2007-11-16 Novartis Ag Uso de derivados 4-piridilmetilftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos.
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm

Also Published As

Publication number Publication date
ATE493979T1 (de) 2011-01-15
EP1378241A1 (fr) 2004-01-07
EP1378240A3 (fr) 2004-01-14
US7132116B2 (en) 2006-11-07
KR20010015755A (ko) 2001-02-26
ATE407683T1 (de) 2008-09-15
EP1391206B1 (fr) 2008-07-02
US20020183385A1 (en) 2002-12-05
US20040115283A1 (en) 2004-06-17
EP1378240B1 (fr) 2008-09-10
CA2307208A1 (fr) 1999-04-22
US7205001B2 (en) 2007-04-17
CY1111379T1 (el) 2015-08-05
US20040096518A1 (en) 2004-05-20
PT2018858E (pt) 2011-03-24
NO20001977L (no) 2000-06-13
DE69840006D1 (de) 2008-10-23
EP1466607A1 (fr) 2004-10-13
HK1061198A1 (en) 2004-09-10
US20050191367A1 (en) 2005-09-01
CY1110057T1 (el) 2015-01-14
US20040197420A1 (en) 2004-10-07
ES2358624T3 (es) 2011-05-12
CY1110055T1 (el) 2015-01-14
HK1061199A1 (en) 2004-09-10
EP2018858A1 (fr) 2009-01-28
DE69840057D1 (de) 2008-11-06
US20040047916A1 (en) 2004-03-11
DK2018858T3 (da) 2013-01-07
US20050100611A1 (en) 2005-05-12
PT1621077E (pt) 2008-11-04
EP1621077A1 (fr) 2006-02-01
EP1374875A2 (fr) 2004-01-02
AU751932B2 (en) 2002-08-29
JP2001519366A (ja) 2001-10-23
PL339909A1 (en) 2001-01-15
US20040161475A1 (en) 2004-08-19
HK1085886A1 (en) 2006-09-08
NO20001977D0 (no) 2000-04-14
CN1282218A (zh) 2001-01-31
ES2312701T3 (es) 2009-03-01
WO1999018798A1 (fr) 1999-04-22
US7179493B2 (en) 2007-02-20
DE69839682D1 (de) 2008-08-14
US7163703B2 (en) 2007-01-16
NZ503973A (en) 2001-09-28
DK1391206T3 (da) 2008-09-01
ES2309258T3 (es) 2008-12-16
ATE399560T1 (de) 2008-07-15
EP1022951A1 (fr) 2000-08-02
DK1378240T3 (da) 2008-12-08
ATE409043T1 (de) 2008-10-15
EP2018858B1 (fr) 2011-01-05
PT1378240E (pt) 2008-11-14
EP1391206A1 (fr) 2004-02-25
AU1089399A (en) 1999-05-03
CY1108363T1 (el) 2014-02-12
US20040197421A1 (en) 2004-10-07
ES2313201T3 (es) 2009-03-01
IL135620A0 (en) 2001-05-20
BR9813085A (pt) 2000-08-22
TR200001959T2 (tr) 2000-11-21
EP1621077B1 (fr) 2008-09-24
DE69842094D1 (de) 2011-02-17
EP1022951A4 (fr) 2002-06-19
EP1378240A2 (fr) 2004-01-07
EP1374875A3 (fr) 2004-01-07
US6875451B2 (en) 2005-04-05
PT1391206E (pt) 2008-08-13
EP1419778A1 (fr) 2004-05-19

Similar Documents

Publication Publication Date Title
DK1621077T3 (da) Farmaceutiske præparater der omfatter arsentrioxid til behandling af ikke-Hodkins lymfom
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
IL150767A (en) Benzophyrene compounds and their use in the manufacture of drugs for the treatment of estrogen-sensitive diseases such as endometrial cancer
DE60040981D1 (de) BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
ATE243692T1 (de) Arylaminderivate und ihre verwendung als antitelomerasemittel
WO2000018439A3 (fr) Utilisation de marqueurs de neoangiogenese pour diagnostiquer et traiter des tumeurs
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
TR199800270T1 (xx) Kanser hastal�klar�n�n ilerlemesini �nlemede flukonazol kullan�m�.
ID22718A (id) Senyawa-senyawa tetrahidropirido
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
ATE456377T1 (de) Behandlung des metastasierenden karzinoms der niere
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
ZA9811598B (en) A substance or composition for the treatment of cancer.
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin